GLS and cancer: Among these, the compound CB-839 is a noncompetitive GLS inhibitor able to inhibit the entry of substrates into the TCA cycle, thus reducing cell viability and cancer stemness, increasing chemosensitivity, and inducing apoptotic cell death in several cancer types [110,111,112,113,114].